LON:STX - Shield Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Shield Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 154.50 +0.50 (+0.32 %) (As of 02/19/2020 04:00 PM ET) Add Compare Today's Range 153Now: GBX 154.50▼ 15650-Day Range 154MA: GBX 167.21▼ 180.5052-Week Range 45Now: GBX 154.50▼ 202Volume40,097 shsAverage Volume48,665 shsMarket Capitalization£181.06 millionP/E Ratio42.92Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. Read More… Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:STX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.shieldtherapeutics.com/ Phone+44-191-5118500Debt Debt-to-Equity Ratio0.26 Current Ratio4.79 Quick Ratio4.57Price-To-Earnings Trailing P/E Ratio42.92 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£14.00 million Price / Sales12.93 Cash FlowGBX 5.37 per share Price / Cash Flow28.75 Book ValueGBX 33.10 per share Price / Book4.67Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares117,189,000Market Cap£181.06 million Next Earnings DateN/A OptionableOptionable Receive STX News and Ratings via Email Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. LSE:STX Rates by TradingView Shield Therapeutics (LON:STX) Frequently Asked Questions What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." What price target have analysts set for STX? 3 equities research analysts have issued 1-year price objectives for Shield Therapeutics' stock. Their forecasts range from GBX 116 to GBX 200. On average, they anticipate Shield Therapeutics' stock price to reach GBX 179 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price. View Analyst Price Targets for Shield Therapeutics. What is the consensus analysts' recommendation for Shield Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics. Has Shield Therapeutics been receiving favorable news coverage? News articles about STX stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Shield Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Shield Therapeutics. Who are some of Shield Therapeutics' key competitors? Some companies that are related to Shield Therapeutics include HLS Therapeutics (HLS), OrganiGram (OGI), ORGANIGRAM-TS (OGI), Hexo (HEXO), HEXO (HEXO), Next Science (NXS), Benchmark (BMK), ICC Labs (ICC), Amryt Pharma (AMYT), Probiotec (PBP), Green Organic Dutchman (TGOD), CannTrust (TRST), ESSA Pharma (EPI), Supreme Cannabis (FIRE) and WeedMD (WMD). What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and Skinbiotherapeutics (SBTX). Who are Shield Therapeutics' key executives? Shield Therapeutics' management team includes the folowing people: Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)Mr. Timothy William Watts, Chief Financial Officer (Age 61)Fleur Wood, Director of Investor RelationsMs. Lucy Bailey, Gen. Counsel & Company Sec.Ms. Suzanne Wood, Group HR Director How do I buy shares of Shield Therapeutics? Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 154.50. How big of a company is Shield Therapeutics? Shield Therapeutics has a market capitalization of £181.06 million and generates £14.00 million in revenue each year. Shield Therapeutics employs 15 workers across the globe.View Additional Information About Shield Therapeutics. What is Shield Therapeutics' official website? The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500. MarketBeat Community Rating for Shield Therapeutics (LON STX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 199 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 336MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: What is a support level?
